MedTrace Logo

De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma

NCT00328770 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2013-06-24

Study results available
· View outcomes & findings →

Summary

This study investigates whether sirolimus could decrease the rate of hepatoma recurrence after liver transplantation in high risk hepatoma patients.

Conditions

  • Liver Carcinoma

Interventions

DRUG

Sirolimus

Sirolimus given intravenously or orally to achieve target levels of 12-20ug/l

Sponsors & Collaborators

  • University of Alberta

    lead OTHER

Principal Investigators

  • Norman M Kneteman, MD · University of Alberta

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-12-31
Primary Completion
2006-03-31
Completion
2006-03-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00328770 on ClinicalTrials.gov